A new study finds most cancer screening guidelines do not clearly spell out the benefits and harms of the recommended actions.
A new study suggests that up to 60 percent of the CT scans, bone scans, and PET scans performed for more than 29,000 Michigan women diagnosed with early breast cancer between 2008 and 2014 could not be medically justified based on retrospective record review.
A new study suggests that one approach to watching for a cancer’s return is being inappropriately used at many hospitals. And it isn’t helping patients survive longer, the research shows.
Researchers at the University of Michigan Kellogg Eye Center have developed a new nanoparticle that uses a tumor cell’s protective mechanism against itself — short-circuiting tumor cell metabolism and killing tumor cells.
One of the most common cancer-causing genes has continuously stymied researchers’ efforts to develop treatments against it. Now, researchers have dug deeper and exposed a key interaction that may contribute to why mutations in KRAS lead to cancer.
Cancer Center researcher Max S. Wicha has received a $6.5 million Outstanding Investigator Award to study cancer stem cells, the small number of cells within a tumor that fuel its growth and spread.
In response to low national vaccination rates for the human papillomavirus, the University of Michigan Comprehensive Cancer Center has joined 69 of the nation’s top cancer centers in issuing a statement urging for increased HPV vaccination for the prevention of cancer.
Nearly 15 percent of patients diagnosed with colorectal cancer were younger than 50, the age at which screening recommendations begin.
A new University of Michigan study found that feeding rats a "nisin milkshake" killed 70-80 percent of head and neck tumor cells after nine weeks and extended survival, said Dr. Yvonne Kapila, a professor at the University of Michigan School of Dentistry.
Millendo Therapeutics, a University of Michigan startup company, announced today that it has entered into an exclusive license agreement with AstraZeneca for the worldwide development and commercialization rights to test a new compound, MLE4901, for the treatment of polycystic ovary syndrome.